These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 2541112

  • 1. In vivo diagnosis and therapy of human tumors with monoclonal antibodies: selection of antibodies and preliminary clinical studies in small cell carcinoma of the lung.
    Mulshine JL, Avis I, Treston AM, Kaspryzyk PG, Nakanishi Y, Mobley C, Carrasquillo JA, Larson SM, Merchant B, Cuttitta F.
    Int J Rad Appl Instrum B; 1989; 16(2):159-62. PubMed ID: 2541112
    [Abstract] [Full Text] [Related]

  • 2. Preclinical evaluation of an anti-autocrine growth factor monoclonal antibody for treatment of patients with small-cell lung cancer.
    Avis IL, Kovacs TO, Kasprzyk PG, Treston AM, Bartholomew R, Walsh JH, Cuttitta F, Mulshine JL.
    J Natl Cancer Inst; 1991 Oct 16; 83(20):1470-6. PubMed ID: 1656058
    [Abstract] [Full Text] [Related]

  • 3. Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer.
    Mulshine JL, Avis I, Treston AM, Mobley C, Kaspryzyk P, Carrasquillo JA, Larson SM, Nakanishi Y, Merchant B, Minna JD.
    Ann N Y Acad Sci; 1988 Oct 16; 547():360-72. PubMed ID: 2853598
    [No Abstract] [Full Text] [Related]

  • 4. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer.
    Kelley MJ, Linnoila RI, Avis IL, Georgiadis MS, Cuttitta F, Mulshine JL, Johnson BE.
    Chest; 1997 Jul 16; 112(1):256-61. PubMed ID: 9228385
    [Abstract] [Full Text] [Related]

  • 5. Autocrine growth factors as therapeutic targets in lung cancer.
    Mulshine JL, Treston AM, Natale RB, Kasprzyk PG, Avis I, Nakanishi Y, Cuttitta F.
    Chest; 1989 Jul 16; 96(1 Suppl):31S-34S. PubMed ID: 2661168
    [No Abstract] [Full Text] [Related]

  • 6. Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer.
    Johnson BE, Kelley MJ.
    Oncology (Williston Park); 1998 Jan 16; 12(1 Suppl 2):11-4. PubMed ID: 9516605
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer.
    Chaudhry A, Carrasquillo JA, Avis IL, Shuke N, Reynolds JC, Bartholomew R, Larson SM, Cuttitta F, Johnson BE, Mulshine JL.
    Clin Cancer Res; 1999 Nov 16; 5(11):3385-93. PubMed ID: 10589749
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies.
    Mendelsohn J.
    Prog Allergy; 1988 Nov 16; 45():147-60. PubMed ID: 3064094
    [No Abstract] [Full Text] [Related]

  • 11. [Gut hormones with activity to modulate cellular growth].
    Yamaguchi K.
    Hum Cell; 1990 Mar 16; 3(1):23-6. PubMed ID: 2083220
    [Abstract] [Full Text] [Related]

  • 12. Nonconstitutive expression of the gastrin-releasing peptide autocrine growth system in human small cell lung carcinoma NCI-H345 cells.
    Aguayo SM, Miller Y, Boose D, Holley M, Portanova LB, Schuyler KD, Kane MA.
    Cell Growth Differ; 1996 May 16; 7(5):563-72. PubMed ID: 8732666
    [Abstract] [Full Text] [Related]

  • 13. Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro.
    Weber S, Zuckerman JE, Bostwick DG, Bensch KG, Sikic BI, Raffin TA.
    J Clin Invest; 1985 Jan 16; 75(1):306-9. PubMed ID: 2981251
    [Abstract] [Full Text] [Related]

  • 14. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.
    Retter MW, Johnson JC, Peckham DW, Bannink JE, Bangur CS, Dresser K, Cai F, Foy TM, Fanger NA, Fanger GR, Woda B, Rock KL.
    Cancer Res; 2005 Jul 15; 65(14):6425-34. PubMed ID: 16024647
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents.
    Mendelsohn J.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):889-92. PubMed ID: 2285602
    [Abstract] [Full Text] [Related]

  • 17. Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.
    Krug LM, Milton DT, Jungbluth AA, Chen LC, Quaia E, Pandit-Taskar N, Nagel A, Jones J, Kris MG, Finn R, Smith-Jones P, Scott AM, Old L, Divgi C.
    J Thorac Oncol; 2007 Oct 20; 2(10):947-52. PubMed ID: 17909358
    [Abstract] [Full Text] [Related]

  • 18. Growth factors and lung cancer.
    Sethi T, Woll PJ.
    Cancer Treat Res; 1995 Oct 20; 72():111-30. PubMed ID: 7702983
    [No Abstract] [Full Text] [Related]

  • 19. Gastrin-releasing peptide (GRP, mammalian bombesin) in the pathogenesis of lung cancer.
    Viallet J, Minna JD.
    Prog Growth Factor Res; 1989 Oct 20; 1(2):89-97. PubMed ID: 2491257
    [Abstract] [Full Text] [Related]

  • 20. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
    Koppán M, Halmos G, Arencibia JM, Lamharzi N, Schally AV.
    Cancer; 1998 Oct 01; 83(7):1335-43. PubMed ID: 9762934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.